UY36455A - Antagonistas del receptor ep3 de prostaglandinas - Google Patents
Antagonistas del receptor ep3 de prostaglandinasInfo
- Publication number
- UY36455A UY36455A UY0001036455A UY36455A UY36455A UY 36455 A UY36455 A UY 36455A UY 0001036455 A UY0001036455 A UY 0001036455A UY 36455 A UY36455 A UY 36455A UY 36455 A UY36455 A UY 36455A
- Authority
- UY
- Uruguay
- Prior art keywords
- prostaglandinas
- antagonists
- receiver antagonists
- receiver
- prostaglandin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente, se proporcionan antagonistas del receptor EP33 de prostaglandinas, procesos para preparar dichos antagonistas y métodos que comprenden la administración de dichos antagonistas a un mamífero que lo necesita.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462095337P | 2014-12-22 | 2014-12-22 | |
US201562259528P | 2015-11-24 | 2015-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36455A true UY36455A (es) | 2016-07-29 |
Family
ID=55077554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036455A UY36455A (es) | 2014-12-22 | 2015-12-18 | Antagonistas del receptor ep3 de prostaglandinas |
Country Status (7)
Country | Link |
---|---|
US (1) | US9738626B2 (es) |
EP (1) | EP3237401B1 (es) |
JP (1) | JP2017538769A (es) |
CA (1) | CA2915470A1 (es) |
TW (1) | TW201632513A (es) |
UY (1) | UY36455A (es) |
WO (1) | WO2016103097A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10336701B2 (en) | 2017-08-10 | 2019-07-02 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists |
US10590083B2 (en) | 2017-08-10 | 2020-03-17 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists |
US10399944B2 (en) | 2017-08-10 | 2019-09-03 | Janssen Pharmaceutica Nv | Pyridin-2-one derivatives of formula (III) useful as EP3 receptor antagonists |
KR20210013084A (ko) | 2018-05-17 | 2021-02-03 | 바이엘 악티엔게젤샤프트 | 치환된 디히드로피라졸로 피라진 카르복스아미드 유도체 |
WO2021094209A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094210A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists |
WO2021094208A1 (en) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Substituted imidazo pyrimidine ep3 antagonists |
WO2022215072A2 (en) | 2021-04-07 | 2022-10-13 | Hadasit Medical Research Services & Development Ltd. | Therapeutic modalities for inhibiting pancreatic beta cell impairment and treating diabetes |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4219483A (en) | 1978-09-11 | 1980-08-26 | Pfizer Inc. | 4-Pyrone prostaglandin antagonists |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
CN1149196C (zh) | 1998-07-06 | 2004-05-12 | 布里斯托尔-迈尔斯斯奎布公司 | 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺 |
MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
EA200300944A1 (ru) | 2001-02-28 | 2004-04-29 | Мерк Энд Ко., Инк. | Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
EA200400980A1 (ru) | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
RS51106B (sr) | 2004-05-12 | 2010-10-31 | Pfizer Products Inc. | Derivati prolina i njihova upotreba kao inhibitora dipeptidil peptidaze iv |
EP1753766A1 (en) | 2004-05-25 | 2007-02-21 | Pfizer Products Inc. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
KR101213912B1 (ko) | 2004-08-26 | 2012-12-18 | 액테리온 파마슈티칼 리미티드 | Crth2 길항제로서의2-설파닐-벤조이미다졸-1-일-아세틱 애시드 유도체 |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
WO2007027630A2 (en) | 2005-08-30 | 2007-03-08 | Smithkline Beecham Corporation | Genes associated with type ii diabetes mellitus |
JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
JP2010511035A (ja) | 2006-11-29 | 2010-04-08 | ファイザー・プロダクツ・インク | スピロケトンアセチルCoAカルボキシラーゼ阻害剤 |
BRPI0811444A2 (pt) | 2007-05-10 | 2014-10-29 | Pfizer Ltd | Derivados de azetidina e seu uso como antagonistas da prostaglandina e2. |
BRPI0811280B8 (pt) | 2007-05-11 | 2021-05-25 | Pfizer | compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
EP2297164A1 (en) | 2008-05-28 | 2011-03-23 | Pfizer Inc. | Pyrazolospiroketone acetyl-coa carboxylase inhibitors |
ES2545231T3 (es) | 2008-05-28 | 2015-09-09 | Pfizer Inc. | Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa |
EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
NZ591027A (en) | 2008-08-28 | 2012-11-30 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
TW201038580A (en) | 2009-02-02 | 2010-11-01 | Pfizer | 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives |
CA2754685A1 (en) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Substituted indazole amides |
EP2604604A1 (en) | 2009-03-11 | 2013-06-19 | Pfizer Inc | Benzofuranyl derivatives used as glucokinase inhibitors |
US20120095028A1 (en) | 2009-03-20 | 2012-04-19 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
WO2010128425A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
US20120052130A1 (en) | 2009-05-08 | 2012-03-01 | Pfizer Inc. | Gpr 119 modulators |
MA33334B1 (fr) | 2009-06-05 | 2012-06-01 | Pfizer | Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119 |
WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
BR112013021366A2 (pt) | 2011-02-23 | 2016-09-13 | Pfizer | imidazo[5,1-f][1,2,4]triazinas para o tratamento de desordens neurológicas |
US8829010B2 (en) | 2011-06-07 | 2014-09-09 | Pfizer Inc. | Pyrazolo[3,4-d]pyrimidine compounds and their use as PDE2 inhibitors and/or CYP3A4 inhibitors |
CA2926568C (en) | 2013-10-09 | 2017-09-05 | Pfizer Inc. | Antagonists of prostaglandin ep3 receptor |
-
2015
- 2015-12-11 JP JP2017533416A patent/JP2017538769A/ja not_active Withdrawn
- 2015-12-11 WO PCT/IB2015/059548 patent/WO2016103097A1/en active Application Filing
- 2015-12-11 EP EP15821169.8A patent/EP3237401B1/en not_active Not-in-force
- 2015-12-16 US US14/970,930 patent/US9738626B2/en not_active Expired - Fee Related
- 2015-12-17 CA CA2915470A patent/CA2915470A1/en not_active Abandoned
- 2015-12-17 TW TW104142513A patent/TW201632513A/zh unknown
- 2015-12-18 UY UY0001036455A patent/UY36455A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW201632513A (zh) | 2016-09-16 |
EP3237401B1 (en) | 2019-03-06 |
WO2016103097A1 (en) | 2016-06-30 |
US9738626B2 (en) | 2017-08-22 |
EP3237401A1 (en) | 2017-11-01 |
JP2017538769A (ja) | 2017-12-28 |
US20160176851A1 (en) | 2016-06-23 |
CA2915470A1 (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36455A (es) | Antagonistas del receptor ep3 de prostaglandinas | |
CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
DOP2017000124A (es) | Agonistas parciales del receptor de insulina | |
DOP2016000224A (es) | Tratamientos combinados con anticuerpos anti-cd38 | |
TWD174683S (zh) | 戒指 | |
TWD171866S (zh) | 腳踏車座墊(一) | |
UY35776A (es) | ?antagonistas de receptor ep3 de prostaglandina?. | |
CO7151512A2 (es) | Inhibidores del nampt | |
UY34682A (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina. | |
BR112016017402A2 (pt) | fusões anti-pcsk9~glp-1 e métodos para uso | |
TWD173762S (zh) | 自行車用頭燈 | |
CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
CL2016002469A1 (es) | Sulfamidasa modificada y su producción | |
GT201400061S (es) | Diseño de motocicleta | |
DOP2017000264A (es) | Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio | |
TWD175782S (zh) | 緩衝器 | |
UA98443U (ru) | Применение коллоидно-изоосмолярная раствора волювен как средства для улучшения перфузии головного мозга при ишемии | |
CO7091168A2 (es) | Tensor para unir elementos estructurales | |
TWD168844S (zh) | 運動用墊 | |
CR20150630S (es) | Motocicleta | |
CO7051029A2 (es) | Proceso para la preparacion de fenilpropanonas sustituidas | |
TWD162428S (zh) | 鞋墊 | |
TN2014000384A1 (fr) | نظام صوتي ذكي وآمن | |
TH1401004274B (th) | อุปกรณ์การล็อกที่นั่งของรถจักรยานยนต์ | |
TWD164930S (zh) | 研磨機 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20220721 |